The Board recalls its decision regarding the Affordable Medicine Facility - malaria ("AMFM") (GF/B18/DP7).
The Board notes that it will vote on the AMFm proposals at its Twentieth meeting. The Board understands that the independent evaluation of AMFm Phase 1 is now estimated to be completed in the second half of 2011.
The Board decides to maintain the AMFm Ad Hoc Committee as a separate committee of the Board for the duration of the AMFm of the AMFm Phase 1 period with the terms of reference set out in Annex 1 to the Report of the AMFm Committee (GF/B19/7).
The Board confirms that the Technical Evaluation Reference Group (TERG) will provide guidance with regard to the technical parameters of the design of the independent evaluation of the AMFm, under the oversight of the AMFm Ad Hoc Committee. Consistent with its previous decisions, the Board confirms that the Secretariat will continue to have responsibility for commissioning of the independent evaluation, under the oversight of the AMFm Ad Hoc Committee.
The Board notes pending WHO guidance that fixed-dosed co-formulations (FDCs) are strongly preferable to co-blistered ACTs and may help to delay resistance to artemisinin. The Board also notes that multiple technical issues need to be taken into account to ensure a smooth transition to an exclusive use of FDC ACTs. The Board urges that WHO expedite finalization of this guidance on FDCs and co-blistered ACTs.
The Board requests its Chair to delegate to the relevant committee(s) the task of identifying and considering options for the Global Fund, within its mandate as a financing institution, to support countries in expediting the transition to FDCs, taking into consideration the implications for quality, supply, pricing and appropriate use of ACTs, and to report back to the Board at its Twentieth meeting.